Overview

Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody for Chronic Lymphocytic Leukemia

Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the safety of Iodine-131 Anti-B1 Antibody, to see what effects it has on patients with CLL and to determine the highest dose of Iodine-131 Anti-B1 Antibody that can be given without causing severe side effects.
Phase:
Phase 1
Details
Lead Sponsor:
Corixa Corporation
Collaborator:
GlaxoSmithKline
Treatments:
Antibodies
Antibodies, Monoclonal
Cadexomer iodine
Immunoglobulins
Iodine
Iodine-131 anti-B1 antibody
Tositumomab I-131